High Expression of Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Jul 20

PMID 35855850

Authors

Yan Chen

Min Zhou

Xuyu Gu

Longfei Wang

Cailian Wang

Affiliations

Soon will be listed here.

Abstract

Background: Lung adenocarcinoma (LUAD) has been recognized as one of the commonest aggressive malignant tumors occurring in humans. The transforming acidic coiled-coil-containing protein 3 () seems to be a probable prognostic marker and treatment target for non-small-cell lung cancer (NSCLC). Nevertheless, there exist no reports on the association between and immunotherapy or other therapeutic interventions in LUAD.

Methods: Premised on the data accessed from The Cancer Genome Atlas- (TCGA-) LUAD, we carried out bioinformatics analysis. The expression in LUAD was analyzed utilizing the GEPIA. A survival module was constructed to evaluate the effect of on the survival of patients with LUAD. Logistic regression was undertaken to examine the relationship between expression and clinical factors. Protein-protein interaction analysis was performed in the GeneMANIA database, and enrichment analysis and identification of predicted signaling pathways were performed using Gene Ontology and Kyoto Encyclopedia of Genes. Additionally, the Cox regression was used to assess the clinicopathologic features linked to the overall survival in TCGA patients. Lastly, we investigated the link between and tumor-infiltrating immune cells (TIICs) through CIBERSORT and the "Correlation" module of GEPIA. The association between TACC3 gene expression and drug response was analyzed using the CellMiner database to predict drug sensitivity.

Results: The outcomes illustrated that was upregulated and considerably correlated with dismal prognosis in LUAD patients. Moreover, the multivariate Cox regression analysis depicted as an independent prognostic marker in LUAD patients. It was also revealed that the expression of was related to clinical stage ( = 0.014), age ( = 0.002), and T classification ( ≤ 0.018). Moreover, we discovered that the expression of was considerably linked to a wide range of TIICs, especially the T cells and NK cells. Single-cell results found that TACC3 was mainly expressed in the immune cells (especially tprolif cells) and malignant cells. TACC3 gene expression was positively correlated with TMB and MSI, and TACC3 may provide a prediction of the efficacy of immunotherapy. Moreover, the correlation analysis between TACC3 gene expression and immune checkpoint gene expression revealed that TACC3 may coordinate the activities of these ICP genes in different signal transduction pathways. TACC3 is related to biological progress (BP), cellular component (CC), and molecular function (MF). The pathways involved in the interaction network involving TACC3 include nonhomologous end-joining, RNA transport, pantothenate and CoA biosynthesis, homologous recombination, and nucleotide excision repair. Furthermore, we investigated the association between the expression of TACC3 and the use of antitumor drugs, and TACC3 was positively correlated with response to most drugs.

Conclusion: The findings from this research offer robust proof that the expression of could be a prognostic marker correlated with TIICs in LUAD. TACC3 can also provide new ideas for immunotherapy as a potential therapeutic target.

Citing Articles

Development and validation of a radiomic prediction model for TACC3 expression and prognosis in non-small cell lung cancer using contrast-enhanced CT imaging.

Bai W, Zhao X, Ning Q Transl Oncol. 2024; 51:102211.

PMID: 39603208 PMC: 11635781. DOI: 10.1016/j.tranon.2024.102211.

References

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

Jung C, Jung J, Park G, Lee A, Kang C, Lee K . Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol Int. 2006; 56(9):503-9. DOI: 10.1111/j.1440-1827.2006.01998.x. View

Ali H, Chlon L, Pharoah P, Markowetz F, Caldas C . Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med. 2016; 13(12):e1002194. PMC: 5154505. DOI: 10.1371/journal.pmed.1002194. View

Raff J . Centrosomes and cancer: lessons from a TACC. Trends Cell Biol. 2002; 12(5):222-5. DOI: 10.1016/s0962-8924(02)02268-7. View

Piekorz R, Hoffmeyer A, Duntsch C, McKay C, Nakajima H, Sexl V . The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J. 2002; 21(4):653-64. PMC: 125348. DOI: 10.1093/emboj/21.4.653. View

Hodgins J, Khan S, Park M, Auer R, Ardolino M . Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest. 2019; 129(9):3499-3510. PMC: 6715409. DOI: 10.1172/JCI129338. View

Toor S, Murshed K, Al-Dhaheri M, Khawar M, Nada M, Elkord E . Immune Checkpoints in Circulating and Tumor-Infiltrating CD4 T Cell Subsets in Colorectal Cancer Patients. Front Immunol. 2020; 10:2936. PMC: 6928042. DOI: 10.3389/fimmu.2019.02936. View

Baxevanis C, Fortis S, Perez S . The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Semin Cancer Biol. 2019; 72:76-89. DOI: 10.1016/j.semcancer.2019.12.018. View

Zhang N, Wang D, Duan Y, Ayarick V, Cao M, Wang Y . The special immune microenvironment of tumor budding and its impact on prognosis in gastric adenocarcinoma. Pathol Res Pract. 2020; 216(6):152926. DOI: 10.1016/j.prp.2020.152926. View

10.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

11.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

12.

Taha E, Ono K, Eguchi T . Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion. Int J Mol Sci. 2019; 20(18). PMC: 6770223. DOI: 10.3390/ijms20184588. View

13.

Ge P, Wang W, Li L, Zhang G, Gao Z, Tang Z . Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomed Pharmacother. 2019; 118:109228. DOI: 10.1016/j.biopha.2019.109228. View

14.

Song Q, Shang J, Yang Z, Zhang L, Zhang C, Chen J . Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. J Transl Med. 2019; 17(1):70. PMC: 6399972. DOI: 10.1186/s12967-019-1824-4. View

15.

Waniczek D, Lorenc Z, Snietura M, Wesecki M, Kopec A, Muc-Wierzgon M . Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer. Arch Immunol Ther Exp (Warsz). 2017; 65(5):445-454. PMC: 5602054. DOI: 10.1007/s00005-017-0463-9. View

16.

Ha G, Kim J, Breuer E, Breuer E . TACC3 is essential for EGF-mediated EMT in cervical cancer. PLoS One. 2013; 8(8):e70353. PMC: 3731346. DOI: 10.1371/journal.pone.0070353. View

17.

Jiang F, Kuang B, Que Y, Lin Z, Yuan L, Xiao W . The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer. Oncol Rep. 2015; 35(1):436-46. DOI: 10.3892/or.2015.4373. View

18.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Uras I, Moll H, Casanova E . Targeting Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. Int J Mol Sci. 2020; 21(12). PMC: 7352653. DOI: 10.3390/ijms21124325. View